Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 242

Results For "launch"

2437 News Found

Hester to commercialize vaccines for animals
News | April 09, 2021

Hester to commercialize vaccines for animals

Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection


Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
News | April 05, 2021

Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19

PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents


Reports on GSK Pharmaceuticals by ICICI Securities
News | April 03, 2021

Reports on GSK Pharmaceuticals by ICICI Securities

GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn


COVID-19 drug Remdesivir now priced at Rs. 899
News | March 25, 2021

COVID-19 drug Remdesivir now priced at Rs. 899

Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.


NPPA brings 80 plus medicines under price regulation
News | March 22, 2021

NPPA brings 80 plus medicines under price regulation

NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.


AstraZeneca Pharma India receives approval for supplying Osimertinib in India
News | March 13, 2021

AstraZeneca Pharma India receives approval for supplying Osimertinib in India

The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.


Govt. receives 215 applications for the 36 products under PLI scheme
News | March 13, 2021

Govt. receives 215 applications for the 36 products under PLI scheme

174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.


NATCO receives approval for Everolimus tablets for the US market
News | March 09, 2021

NATCO receives approval for Everolimus tablets for the US market

NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.


Vivimed Labs receives products approvals from Uzbekistan
News | March 09, 2021

Vivimed Labs receives products approvals from Uzbekistan

Vivimed strategy is to increase its share of Branded products in CIS Markets.